Molecular Imaging of Prostate Cancer with PET

Molecular imaging is paving the way for precision and personalized medicine. In view of the significant biologic and clinical heterogeneity of prostate cancer, molecular imaging is expected to play an important role in the evaluation of this prevalent disease. The natural history of prostate cancer spans from an indolent localized process to biochemical relapse after radical treatment with curative intent to a lethal castrate-resistant metastatic disease. The ongoing unraveling of the complex tumor biology of prostate cancer uniquely positions molecular imaging with PET to contribute significantly to every clinical phase of prostate cancer evaluation. The purpose of this article was to provide a concise review of the current state of affairs and potential future developments in the diagnostic utility of PET in prostate cancer.

[1]  Mohsen Beheshti,et al.  Prostate cancer: role of SPECT and PET in imaging bone metastases. , 2009, Seminars in nuclear medicine.

[2]  Yong Q. Chen,et al.  Lipids and prostate cancer. , 2012, Prostaglandins & other lipid mediators.

[3]  J. Humm,et al.  Diversity of biology in castrate resistant prostate cancer , 2009 .

[4]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[5]  S. Groshen,et al.  Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer , 2012, Clinical nuclear medicine.

[6]  A. Kibel,et al.  11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction , 2013, The Journal of Nuclear Medicine.

[7]  L. Bachmann,et al.  The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. , 2013, European urology.

[8]  J. Presti,et al.  Does the yield of prostate cancer biopsy and repeat biopsy justify the frequency of their use? , 2008, Nature Clinical Practice Urology.

[9]  Martin G Pomper,et al.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen. , 2013, Current topics in medicinal chemistry.

[10]  V. Ambrosini,et al.  Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  M. Picchio,et al.  11C-Choline PET/CT and PSA kinetics , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  M. Morris,et al.  Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer* , 2008, Journal of Nuclear Medicine.

[13]  Operational Characteristics Of 11 C-Choline PET/CT For Prostate Cancer Patients With Biochemical Recurrence Following Initial Treatment. , 2012 .

[14]  S. Ramin,et al.  Application of 11C‐acetate positron‐emission tomography (PET) imaging in prostate cancer: systematic review and meta‐analysis of the literature , 2013, BJU international.

[15]  F. Hamdy,et al.  Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer , 2009, BJU international.

[16]  D. Schuster,et al.  Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. , 2013, Nuclear medicine and biology.

[17]  Randy S. Schrecengost,et al.  Molecular pathogenesis and progression of prostate cancer. , 2013, Seminars in oncology.

[18]  S. Groshen,et al.  Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[19]  D. Rubello,et al.  Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis , 2013, Clinical nuclear medicine.

[20]  F. Bowman,et al.  Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. , 2011, Radiology.

[21]  H. Jadvar,et al.  Competitive advantage of PET/MRI. , 2014, European journal of radiology.

[22]  Felix Nensa,et al.  Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results , 2013, Investigative radiology.

[23]  F DuBois Bowman,et al.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  J. Lang,et al.  Current controversies in the management of biochemical failure in prostate cancer. , 2012, Clinical advances in hematology & oncology : H&O.

[25]  S. Larson,et al.  Molecular imaging of prostate cancer , 2012, Current opinion in urology.

[26]  Michael J. Welch,et al.  In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. , 2010, Bioconjugate chemistry.

[27]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[28]  H. Jadvar.  Molecular imaging of prostate cancer: PET radiotracers. , 2012, AJR. American journal of roentgenology.

[29]  V. Lowe,et al.  Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. , 2013, The Journal of urology.